Pioneering a New Frontier in Drug Discovery

Spun out of the MIT Media Lab, DeepCure has developed an AI/ML-based drug discovery platform that leverages MolDB, its proprietary database of over 1 trillion chemistries, to find novel small molecule drugs for previously undruggable targets. Instead of merely improving on physics-based modeling or optimizing binding associations, DeepCure leverages novel chemistry space to deliver high quality scaffolds for effective therapeutics.

A Comprehensive Platform to Expand the Universe of Druggable Enzymes

Traditional small-molecule drug development has focused on active and allosteric sites, but many targets prove to be intractable through this approach. Exo Therapeutics focuses on development of new therapeutics by identifying a novel class of targets called exosites. Exosites are distal and unique from the traditional sites, and exosite-targeted therapeutics may modulate binding affinity between an enzyme and a substrate without affecting other activities, while also diminishing competitive binding and off-target effects.

Drugging the Undruggable for the Benefit of Humankind

PhoreMost has developed a next-generation phenotypic screening platform called SITESEEKER® that can discern the best new targets for future therapy and crucially, how to drug them. This has the potential to significantly increase the diversity of novel therapeutics for cancer and other unmet diseases. Based on the Company's core proprietary PROTEINi® technology, SITESEEKER systematically unmasks cryptic druggable sites across the entire human genome and directly links them to useful therapeutic functions in a live-cell context.

Biopolymers to Engineer Superior Biopharmaceuticals

Valitor is developing a pipeline of biopharmaceuticals using a proprietary platform technology that originated at UC Berkeley. Their products are designed to achieve previously unattainable pharmacological properties, thereby overcoming key challenges for major market indications. By leveraging established clinical mechanisms of action, Valitor can substantially de-risk the development of best-in-class therapies.